RO4929097: Phase Ib data

Data from 34 patients with advanced sarcomas in the Phase Ib portion of an open-label, U.S. Phase Ib/II trial showed that once-daily 150 mg oral vismodegib plus once-daily 10 and 15 mg RO4929097 was well tolerated with no dose-limiting toxicities (DLTs) reported. Systemic exposure (peak plasma concentration and area under the curve (AUC) over 0-24 hours) of RO4929097 was about 70% lower in patients who received vismodegib plus RO4929097 vs. RO4929097 alone. The Phase II portion of the trial is evaluating once-daily 15 mg RO4929097, the recommended dose from the Phase Ib portion, alone and in combination with once-daily 150 mg vismodegib. The Memorial Sloan-Kettering Cancer Center is sponsoring the trial. Data will be presented at the American Society of Clinical Oncology meeting in Chicago in June. ...